Irina Ciortescu Roxana Nemteanu Liliana Gheorghe Corina Hincu Liliana Fortu Oreste Chiriac Andreea Clim Alina Plesa

Abstract

Ulcerative colitis (UC) is a chronic inflammatory condition, with a relapsing-remitting course. The case presented poses some valid questions regarding short-term and long-term management of patients with UC, and if the outcome (colectomy) could have been delayed or even prevented. Rectal bleeding is a cardinal symptom in patients with UC and it occurs among all patients during active disease. Massive rectal bleeding is an uncommon, but serious, complication of UC accounting for 0.1-1.4% of admissions. It is, nonetheless, noteworthy that instances of acute significant lower gastrointestinal bleeding accompanied by hemodynamic instability are infrequent. The rate of colectomy appears to be positively impacted by biological treatment. However, a refractory condition is still the primary reason for surgery, indicating a pressing need for new treatment approaches. Here we present the case of a young male patient who developed massive rectal bleeding and underwent emergent colectomy with ileostomy while having clinical and biological remission (normal calprotectin levels) at week 10 of Vedolizumab treatment.

##plugins.themes.bootstrap3.article.details##

Keywords

ulcerative colitis, massive rectal bleeding, emergency colectomy, calprotectin value

References
1. Gallo G, Kotze PG, Spinelli A. Surgery in ulcerative colitis: When? How? Best Pract Res Clin Gastroenterol. 2018;32-33:71-78. doi: 10.1016/j.bpg.2018.05.017. PMID: 30060941.
2. Miranda-Bautista J, Diéguez L, Rodríguez-Rosales G, Marín-Jiménez I, Menchén L. Cases report: severe colonic bleeding in ulcerative colitis is refractory to selective transcatheter arterial embolization. BMC Gastroenterol. 2019;19(1):55. doi: 10.1186/s12876-019-0970-8. PMID: 30991964; PMCID: PMC6469077.
3. Kolehmainen S, Lepistö A, Färkkilä M. Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016. Scand J Gastroenterol. 2019;54(6):707-711. doi: 10.1080/00365521.2019.1620326. PMID: 31136207.
4. Pardi DS, Loftus EV Jr, Tremaine WJ, et al. Acute major gastrointestinal hemorrhage in inflammatory bowel disease. Gastrointest Endosc. 1999;49(2):153-7. doi: 10.1016/s0016-5107(99)70479-7. PMID: 9925691.
5. Macaluso FS, Cavallaro F, Felice C, et al. Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. Dig Liver Dis. 2019;51(5):613-620. doi: 10.1016/j.dld.2019.01.018. PMID: 30826279.
6. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci. 1993;38(6):1137-1146. doi: 10.1007/BF01295733. PMID: 8508710.
7. Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut. 1990;31(3):329-33. doi: 10.1136/gut.31.3.329. PMID: 2323599; PMCID: PMC1378277.
8. Rodríguez C, Elosua A, Prieto C, et al. Colectomy rate in ulcerative colitis 15 years after diagnosis: Results from the 2001-2003 Navarra cohort. Gastroenterol Hepatol. 2022;45(1):1-8. English, Spanish. doi: 10.1016/j.gastrohep.2020.11.016. PMID: 33545242.
9. Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12(7):543-550. doi: 10.1097/01.MIB.0000225339.91484.fc. PMID: 16804390.
10. Sahami S, Konté K, Buskens CJ, et al. Risk factors for proximal disease extension and colectomy in left-sided ulcerative colitis. United European Gastroenterol J. 2017;5(4):554-562. doi: 10.1177/2050640616679552. PMID: 28588887; PMCID: PMC5446151.
11. Wilkens R, Dolinger M, Burisch J, Maaser C. Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. Gastroenterology. 2022;162(5):1476-1492. doi: 10.1053/j.gastro.2021.10.052. PMID: 34995530.
12. Khaki-Khatibi F, Qujeq D, Kashifard M, et al. Calprotectin in inflammatory bowel disease. Clin Chim Acta. 2020;510:556-565. doi: 10.1016/j.cca.2020.08.025. PMID: 32818491; PMCID: PMC7431395.
13. Malvão LDR, Madi K, Esberard BC, et al. Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis. Medicine (Baltimore). 2021;100(3):e24058. doi: 10.1097/MD.0000000000024058. PMID: 33546007; PMCID: PMC7837839.
14. Vicente-Steijn R, Jansen JM, Bisheshar R, Haagen IA. Analytical and clinical performance of the fully-automated LIAISONXL calprotectin immunoassay from DiaSorin in IBD patients. Pract Lab Med. 2020;21:e00175. doi: 10.1016/j.plabm.2020.e00175. PMID: 32637525; PMCID: PMC7327250.
15. Henriksen M, Jahnsen J, Lygren I, et al C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57(11):1518-1523. doi: 10.1136/gut.2007.146357. PMID: 18566104.
16. Mak LY, Tong TSM, Cheung KS, et al. Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2020;11(3):e00138. doi: 10.14309/ctg.0000000000000138. PMID: 32132451; PMCID: PMC7145039.
17. Kedia S, Ahuja V, Tandon R. Management of acute severe ulcerative colitis. World J Gastrointest Pathophysiol. 2014;5(4):579-588. doi: 10.4291/wjgp.v5.i4.579. PMID: 25401001; PMCID: PMC4231522.
18. Holvoet T, Lobaton T, Hindryckx P. Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clin Exp Gastroenterol. 2021;14:71-81. doi: 10.2147/CEG.S197719. PMID: 33727846; PMCID: PMC7955027.
19. Croft A, Lord A, Radford-Smith G. Markers of Systemic Inflammation in Acute Attacks of Ulcerative Colitis: What Level of C-reactive Protein Constitutes Severe Colitis? J Crohns Colitis. 2022;16(7):1089-1096. doi: 10.1093/ecco-jcc/jjac014. PMID: 35147694; PMCID: PMC9351978.
20. Bregnbak D, Mortensen C, Bendtsen F. Infliximab and complications after colectomy in patients with ulcerative colitis. J Crohns Colitis. 2012;6(3):281-286. doi: 10.1016/j.crohns.2011.08.014. PMID: 22405163.
21. Teeuwen PH, Stommel MW, Bremers AJ, et al. Colectomy in patients with acute colitis: a systematic review. J Gastrointest Surg. 2009;13(4):676-686. doi: 10.1007/s11605-008-0792-4. PMID: 19132451.
22. Sandborn WJ, Colombel JF, Panaccione R, et al. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. J Crohns Colitis. 2019;13(2):172-181. doi: 10.1093/ecco-jcc/jjy149. PMID: 30285104; PMCID: PMC6357899.
23. Hanžel J, Sever N, Ferkolj I, et al. Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease. United European Gastroenterol J. 2019;7(6):741-749. doi: 10.1177/2050640619840211. PMID: 31316778; PMCID: PMC6620872.
How to Cite
Emergency colectomy for massive rectal bleeding in a patient with well-controlled ulcerative colitis receiving Vedolizumab. (2023). Archive of Clinical Cases, 10(3), Arch Clin Cases. 2023;10(3):133-137. https://ojsupgrade.com/index.php/acc/article/view/983
Section
Case Reports

How to Cite

Emergency colectomy for massive rectal bleeding in a patient with well-controlled ulcerative colitis receiving Vedolizumab. (2023). Archive of Clinical Cases, 10(3), Arch Clin Cases. 2023;10(3):133-137. https://ojsupgrade.com/index.php/acc/article/view/983